Epitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian Cancer

Epitopea, a biotechnology company focused on developing novel immunotherapies, today announced that its Clinical Trial Application (CTA) for OVACT, a Phase 1b/2 clinical trial evaluating CryptiVax-1001 in patients with advanced high-grade serous ovarian cancer, has been approved by the relevant regulatory authority. The OVACT trial will be led by Professor Susana Banerjee, a leading oncologist at The Royal Marsden, as Chief Investigator.